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Abstract
Background: Inflammation and inflammatory biomarkers play an important role in atherosclerosis
and cardiovascular disease. Little information is available, however, on time course of serum
markers of inflammation after stroke.
Methods: First ischemic stroke patients ≥40 years old had levels of high-sensitivity C-reactive
protein (hsCRP), serum amyloid A (SAA), and fibrinogen measured in plasma samples drawn at 1,
2, 3, 7, 14, 21 and 28 days after stroke. Levels were log-transformed as needed, and parametric and
non-parametric statistical tests were used to test for evidence of a trend in levels over time. Levels
of hsCRP and SAA were also compared with levels in a comparable population of stroke-free
participants.
Results: Mean age of participants with repeated measures (n = 21) was 65.6 ± 11.6 years, and 13
(61.9%) were men, and 15 (71.4%) were Hispanic. Approximately 75% of patients (n = 15) had mild
strokes (NIH Stroke Scale score 0–5). There was no evidence of a time trend in levels of hsCRP,
SAA, or fibrinogen for any of the markers during the 28 days of follow-up. Mean log(hsCRP) was
1.67 ± 1.07 mg/L (median hsCRP 6.48 mg/L) among stroke participants and 1.00 ± 1.18 mg/L
(median 2.82 mg/L) in a group of 1176 randomly selected stroke-free participants from the same
community (p = 0.0252).
Conclusion: Levels of hsCRP are higher in stroke patients than in stroke-free subjects. Levels of
inflammatory biomarkers associated with atherosclerosis, including hsCRP, appear to be stable for
at least 28 days after first ischemic stroke.
Background
Basic and clinical studies provide evidence that inflamma-
tion plays a crucial role in atherosclerosis and cardiovas-
cular disease [1]. Despite a growing literature on the role
of acute phase proteins, particularly high-sensitivity C-
reactive protein (hsCRP), and other inflammatory mark-
ers in risk stratification and prediction of outcomes
among patients with cardiovascular disease [2-6], very lit-
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tle is known about the role of these markers in predicting
outcome in patients with cerebrovascular disease. Some
investigators have suggested that levels of acute phase
reactants predict prognosis after stroke [7-13], although a
recent review concluded that there was insufficient data
available to recommend testing for these markers in
stroke patients at present [14]. Little information is avail-
able, however, on the time course of serum markers of
inflammation and related proteins after stroke. This con-
sensus statement [14] also concluded that further studies
were needed to determine the time course of levels of
these markers after stroke.
Our objective was to determine the stability of levels of
inflammatory biomarkers after ischemic stroke. We meas-
ured plasma levels of acute phase proteins at seven pre-
specified time points up to 28 days in patients with
ischemic stroke and assessed for trends in these values. We
also compared these levels to those in a comparable
stroke-free population.
Methods
The Northern Manhattan Study (NOMAS) includes a pop-
ulation-based incident ischemic stroke follow-up study in
a multi-ethnic, urban population. The methods of patient
identification and enrollment have been described in pre-
vious publications [15-17]. Briefly, stroke patients were
enrolled if they: (1) were diagnosed with a first stroke; (2)
were over age 40, and (3) resided in Northern Manhattan
for ≥3 months in a household with a telephone. For this
analysis, a subsample (n = 21) of hospitalized ischemic
stroke patients who had blood collected at seven pre-spec-
ified time intervals after stroke were included [17]. The
study was approved by the CUMC Institutional Review
Board. All participants gave consent directly or through a
surrogate when appropriate.
Data were collected through interviews by trained
research assistants, and physical and neurological exami-
nations were conducted by study neurologists, as previ-
ously described [15-17]. When possible, data were
obtained directly from subjects using standardized data
collection instruments. When the subject was unable to
provide answers, a proxy knowledgeable about the sub-
ject's history was interviewed. Race-ethnicity was based
upon self-identification. Medical history was determined
using standardized questions adapted from the Behavio-
ral Risk Factor Surveillance System from the Centers for
Disease Control and Prevention [18]. Hypertension was
defined as a history of hypertension or use of anti-hyper-
tensive medications, and diabetes mellitus was defined by
a fasting blood glucose level ≥126 mg/dl, the subject's
self-report of such a history, or insulin or oral hypoglyc-
emic use.
Stroke diagnostic evaluation included computerized tom-
ography and/or magnetic resonance imaging of the brain,
ultrasound evaluation of the extracranial and intracranial
cerebral vessels, and transthoracic or transesophageal
echocardiogram as appropriate. Assessment of stroke sub-
type using modified TOAST (Trial of Org 10172 in Acute
Stroke Treatment) criteria was determined by a consensus
of stroke neurologists, using all available information, as
described in a previous publication [19]. Baseline stroke
severity was assessed using a derived National Institutes of
Health Stroke Scale (NIHSS), and categorized as mild (0–
5), moderate (6–13) or severe (≥14) [16].
Measurement of acute phase proteins
Both serum and plasma (in EDTA) samples were collected
in the morning at days 1, 2, 3, 7, 14, 21, and 28 after
stroke onset. The mean number of hospital days for the
patient sample was 11.7 ± 18.7 days and 74 samples were
drawn in the hospital and the remainder was collected
after discharge. All blood tubes were centrifuged at 3000 g
for 10 minutes. Serum and plasma were immediately sep-
arated, aliquoted and stored at -70°C until specimens
could be assayed. High sensitivity C-reactive protein
(hsCRP), serum amyloid A (SAA) and fibrinogen were
measured using plasma samples in the Columbia Univer-
sity Medical Center laboratory using the BNII system
(Dade-Behring, Deerfield, IL). The intra-assay and inter-
assay coefficients of variation were, respectively, as fol-
lows: for hsCRP, 1.8% and 4.5%; for SAA, 7.2% and 6.1%;
and for fibrinogen, 1.6% and 5.7%.
Statistical analyses
Statistical analyses were conducted using SAS Version 8.2
(SAS Institute, Cary, NC). Means and their standard devi-
ations of hsCRP, SAA, and fibrinogen were calculated.
Levels of all markers were log-transformed before analysis
to stabilize the variance. Mean log-transformed values for
each marker were compared across groups defined by
demographic characteristics, stroke characteristics (NIHSS
and diagnostic subtype), and risk factors. Tests for time
trends were performed using both parametric and non-
parametric methods. Random effects models were used to
calculate the adjusted differences between mean values at
each time point while taking the correlation among the
repeated measurements into account. The best model for
all outcomes was the model with linear, quadratic, and
cubic time trends. Friedman's test was also used to test for
statistical significance of differences between the markers
at each time point without assuming multivariate normal-
ity. The Welch modified two-sample t-test was used to test
for differences between the marker levels in the sample of
stroke patients and a sample of stroke-free participants.
Throughout, Type I error of the test was set as 0.05.BMC Neurology 2006, 6:37 http://www.biomedcentral.com/1471-2377/6/37
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Results
Table 1 lists the baseline demographic characteristics and
vascular disease risk factor profile of the 21 participants.
The mean age of the subjects was 65.6 ± 11.6 years, and
61.9% (n = 13) were male. The prevalence of vascular risk
factors was high. Previous history of cardiovascular dis-
ease was also prevalent (38.1% had a history of coronary
artery disease). Most had mild strokes (71.4%, n = 15),
23.8% (n = 5) had moderate strokes, and only 1 had a
severe stroke.
There was no evidence of a time trend in levels of hsCRP,
SAA, or fibrinogen for any of the markers during the 28
days of follow-up (Table 2, Figure). Results were similar
using non-parametric tests. Although mean hsCRP
increased from day 1 (8.08 ± 6.54 mg/L) to day 2 (16.42
± 24.71 mg/L) and remained elevated throughout the
period of follow-up (day 28: 20.89 ± 35.40 mg/L), this
was not statistically significant.
In a random effect model adjusted for measurement day,
age, sex, race-ethnicity, history of hypertension, diabetes
mellitus, current smoking, coronary artery disease, stroke
subtype, and stroke severity, log(hsCRP) was associated
with current smoking (beta = 2.46 ± 1.22, p = 0.0469) and
stroke severity (beta = 0.15 ± 0.08, p = 0.0539), but not
with other risk factors. On day 1, mean log(hsCRP) was
1.54 ± 1.18 mg/L among current smokers versus 2.04 ±
0.58 mg/L among non-smokers. Mean log(hsCRP) was
1.54 ± 1.11 mg/L among those with mild stroke (NIH
stroke scale <6) versus 2.04 ± 0.98 among those with
moderate to severe stroke (NIH stroke scale ≥6).
In a random effect model SAA was associated with sex (p
= 0.0017) and history of diabetes mellitus (p = 0.0349),
but not with stroke severity, smoking, or other risk factors.
Mean values of log(SAA) were 3.16 ± 0.55 mg/L for those
with diabetes mellitus compared with 1.59 ± 1.14 mg/L
for those without diabetes. Fibrinogen levels were not
associated with patient characteristics.
In a group of 1176 stroke-free subjects (mean age 68.9 ±
10.0 years) drawn from the same underlying population
as part of an ongoing prospective cohort study among
stroke patients, mean levels of hsCRP were lower than the
day 1 values in this population of stroke patients. The
mean log(hsCRP) was 1.00 ± 1.18 (median hsCRP 2.82
mg/L) among stroke-free participants, and 1.67 ± 1.07
(median 6.48 mg/L) among stroke patients (p = 0.0252).
Mean log(SAA) was not higher among stroke patients
(1.78 ± 1.20 mg/L) than 1122 stroke-free participants
(1.52 ± 0.80 mg/L; p = 0.4031). Median SAA among
stroke patients was 5.70 versus 4.60 mg/L among stroke-
free participants.
Discussion
We found that levels of the acute phase proteins hsCRP,
SAA, and fibrinogen are stable after stroke for at least one
month in patients with their first mild to moderate
ischemic strokes. There is no significant time trend in lev-
els over this period of time. Although we did not have
available levels of these proteins in these patients prior to
their stroke, the levels of hsCRP in a comparable popula-
tion of stroke-free participants was significantly lower,
suggesting that hsCRP levels are higher in those with
recent stroke. We think this is most likely because hsCRP
levels increase at the time of stroke, although we cannot
exclude the possibility that hsCRP is elevated in those
stroke-free individuals who subsequently go on to
develop stroke [2,14]. It thus appears that if levels of
hsCRP increase at the time of stroke, they remain elevated
for at least one month. Whether levels decrease after that
time is not addressed by these data.
Several epidemiological studies provide evidence that
inflammatory markers, particularly hsCRP, predict inci-
dent ischemic stroke in stroke-free populations [14].
Some investigators have provided evidence that inflam-
matory markers measured at the time of ischemic stroke
predict future recurrent ischemic events [14], including
stroke [13]. The prognostic significance of inflammatory
markers after a vascular event has already occurred has
been assessed in relatively few studies, however, particu-
larly with regard to recurrent stroke as an outcome.
Among stroke patients, IL-6 and IL-1 receptor antagonist,
but not TNFα, measured at baseline were independent
predictors of worsening in the first 24 hours after stroke
[7,8]. Others found that hsCRP levels above 10.1 when
Table 1: Baseline characteristics of study population
Number of participants 21
Age, mean ± SD, y 65.6 ± 11.6
Male, N (%) 13 (61.9)
Race-ethnicity, N (%)
Non-Hispanic White, 4 (19.1)
Non-Hispanic Black 2 (9.5)
Hispanic 15 (71.4)
Risk factors, N (%)
History of coronary artery disease 8 (38.1)
Current smoking 4 (19.1)
Diabetes mellitus 3 (14.3)
Hypertension 14 (66.7)
Hypercholesterolemia 7 (33.3)
NIH Stroke Scale score, N (%)
0–5 15 (71.4)
6–13 5 (23.8)
≥14 1 (4.8)
Stroke etiologic subtype, N (%)
Atherosclerotic 2 (9.5)
Lacunar 7 (33.3)
Embolic 1 (4.8)
Cryptogenic 11 (52.4)BMC Neurology 2006, 6:37 http://www.biomedcentral.com/1471-2377/6/37
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measured within 72 hours of stroke predicted mortality
over 4 years [10]. Others found that the measurement of
CRP at 24 or 48 hours, but not at admission, also pre-
dicted outcome [12]. In one study, hsCRP levels ≥15 mg/
L at discharge were associated with occurrence of a new
vascular event or death at 1 year [11]. HsCRP levels in the
highest quintile measured at least 3 months after a first
ischemic stroke or TIA were associated with an increased
Mean values of log-transformed levels of acute phase proteins over time Figure 1
Mean values of log-transformed levels of acute phase proteins over time.
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Table 2: Mean levels of log-transformed measures during 28 days of follow-up
Day N log(CRP) mg/L log (SAA) mg/L log (fibrinogen) mg/dL
1 16 0.72 ± 0.46 0.77 ± 0.51 2.64 ± 0.09
2 15 0.91 ± 0.53 0.97 ± 0.67 2.65 ± 0.11
3 20 0.99 ± 0.51 1.05 ± 0.71 2.70 ± 0.06
7 20 0.87 ± 0.56 0.93 ± 0.65 2.69 ± 0.08
14 19 0.90 ± 0.60 0.88 ± 0.60 2.60 ± 0.37
21 18 0.76 ± 0.61 0.85 ± 0.65 2.66 ± 0.12
28 17 0.91 ± 0.58 0.93 ± 0.64 2.66 ± 0.09
P* 0.7005 0.4764 0.6382
* p for trend over time using random effect models.BMC Neurology 2006, 6:37 http://www.biomedcentral.com/1471-2377/6/37
Page 5 of 6
(page number not for citation purposes)
risk of subsequent stroke or MI in another study [9]. In a
nested case-control analysis of a large clinical trial popu-
lation, elevated levels of both fibrinogen and hsCRP inde-
pendently predicted recurrent ischemic stroke [13].
The time course of inflammatory markers and acute phase
reactant proteins after ischemic events has been investi-
gated in relatively few studies, particularly with regard to
stroke. In one study [20], levels of fibrinogen and leuko-
cyte count, but not hsCRP, were elevated up to one year
after acute stroke compared to healthy control subjects.
These data were limited to blood samples drawn at stroke
onset, 6 weeks, 6 months, and 1 year after enrollment. In
another study [21], levels of hsCRP measured at hospital
discharge were more strongly associated with prognosis
than measurements made at admission or between 48
and 72 hours. There was evidence of a change in hsCRP
levels during hospitalization, but with some patients
showing an increase and others a decrease in levels. Our
data suggest that, on average, levels measured within the
first month after stroke may not vary significantly, and
that timing of measurement may not be crucial if levels
within one month are used for prognostication. Cur-
rently, however, while several studies have indicated
hsCRP may be used for purposes of prognostication [10-
12], there is no consensus that this is appropriate [14].
We also found an association of post-stroke levels of
hsCRP with smoking and stroke severity. Other studies
have found an association between hsCRP levels and
smoking in disease-free individuals [22-24], but few stud-
ies have evaluated this association in patients after stroke.
In those studies in which this was assessed, no association
was found [9-12]. We may have had greater power to
detect associations, however, because of the greater
number of measurements made at multiple time points.
Many other inflammatory markers are similarly elevated
in smokers [2], moreover, and this may provide a mecha-
nism through which smoking increases the risk of vascular
disease. Similar to some [10,11], but not all [9], other
studies, we found an association of post-stroke hsCRP to
stroke severity. Serum amyloid A has not been systemati-
cally studied in stroke patient populations.
Diabetes mellitus has also been associated with levels of
hsCRP in cross-sectional analyses of stroke-free individu-
als [25,26], and the increased risk associated with elevated
levels of hsCRP may be attenuated or absent in study par-
ticipants with a history of diabetes [26,27]. Previous stud-
ies in stroke patients, however, have not demonstrated
differences in hsCRP levels according to history of diabe-
tes mellitus [9-12,21]. In studies that have found an effect
of elevated hsCRP on risk of recurrent stroke, moreover,
analyses were not adjusted for diabetes mellitus [13]. Fur-
ther studies will be needed to determine whether the
prognostic value of hsCRP after stroke is present in
patients with diabetes mellitus.
Levels of inflammatory markers may remain elevated for
at least a month after stroke for several reasons. First,
patients with ischemic stroke may suffer ongoing compli-
cations, such as infections and deep venous thrombosis,
which lead to persistent elevations in these markers. The
patients in our study, however, were largely free of such
complications and had milder strokes than would be
expected among patients with these complications. Sec-
ond, levels of acute phase reactants could be markers of an
increased inflammatory state that first predisposed the
patient to stroke, and we cannot exclude this possibility
on the basis of our data. We found few correlations
between levels of acute phase proteins and other vascular
risk factors, however. Third, the cerebral or vascular injury
caused by stroke and the subsequent recovery may lead to
an upregulation in the production of these markers, and
this process may persist for a month or longer [20]. Fur-
ther studies in larger populations of patients, with correla-
tion with stroke severity and markers of cerebral injury,
are needed to resolve these questions.
A strength of our study is the availability of levels of sev-
eral markers at multiple time points after ischemic stroke.
Most studies have relied on a relatively small number of
measurements. We also focused on patients with milder
strokes, which limits the likelihood of confounding due
to major medical complications.
There are also limitations to our study. Because of the
requirement for frequent phlebotomy, we studied a rela-
tively small number of participants, which limited our
power to detect changes over time and between patient
subgroups. We also do not have available measurements
beyond 28 days. Future studies should assess these mark-
ers at longer time intervals after stroke.
Conclusion
Levels of hsCRP are higher in stroke patients than in
stroke-free subjects. Levels of inflammatory biomarkers
associated with atherosclerosis, including hsCRP, appear
to be stable for at least 28 days after first ischemic stroke.
This information may be useful in planning future studies
of the effect of inflammatory biomarkers on prognosis
after stroke.
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